WFIPP has the chance to benefit from the continuous and valuable support of its sponsors. Several pharmaceutical companies ensure through their involvement with WFIPP’s activities and projects the sustainability of our association’s work in the fight against incontinence, pelvic pain and pelvic disorders.
Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into VALUE for patients.
Amara Therapeutics is an Irish-based Digital Therapeutics company who develop app-based treatments for patients suffering from Overactive Bladder (OAB). The company is a spin out from the University of Galway in Ireland and their mission is to make clinically proven, guideline recommended, behavioural therapy available to all OAB patients in a convenient and cost-effective manner.
The company’s first product is called BladderBoss (www.bladderboss.com) which is a direct-to-consumer app-based program that helps women better manage their bladder health, with a focus on reducing the impact of OAB.Read more
“Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people’s lives. With challenges facing families and healthcare systems – such as rising costs, aging populations, and the burden of chronic disease – we are using the power of technology to take healthcare Further, Together.
Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value – for healthcare systems, providers, and the people they serve.
MUVON Therapeutics AG is a clinical stage Life Science spin-off from the University of Zurich developing a cell therapy platform for the regeneration of skeletal muscle tissue, not only repairing damaged tissue but also increasing the regenerative potential of weakened muscles.
Our initial area of focus is the treatment of stress urinary incontinence in women, supporting them respectfully throughout their journey to a healthy life.
Novuqare (Novuqare.com) works together with healthcare professionals and patients on research and projects to initiate innovations and to develop clinically relevant healthcare solutions.
Since our founding in 2011 we have developed long-term collaborations with several renowned healthcare partners.
Our mission is to improve the care and health of patients by developing unique, innovative, medical-technological applications and services.
One of our most revolutionary and impactful developments is MAPLe®: the pelvic floor in high definition for a detailed diagnosis and targeted treatment.
Bowel Research UK is funding life-changing research into bowel cancer and other bowel diseases. Every year over 16,000 people die from bowel cancer in the UK and over a million suffer from bowel disease.By researching cutting edge treatments and investing in the best science, we’re saving and improving people’s lives. Bowel Research UK was founded in 2020 following a merger between two well-respected charities: Bowel & Cancer Research and Bowel Disease Research Foundation (BDRF). We’re the UK’s leading specialist bowel cancer and bowel disease research charity and our research is saving and improving lives. Bringing together researchers, patients and their families, healthcare professionals, decision makers and those with an interest in bowel cancer and bowel disease is the ambition of Bowel Research UK. Through funding world-class research, investing in the next generation of researchers and raising awareness we are making and will continue to make a real difference.